The decision was based on evidence for a beneficial effect of G-CSF in glycogenosis-associated IBD-like disease [3] as well as a previous randomized controlled trial in patients with Crohn’s disease showing that GM-CSF was able to decrease disease activity and to improve quality of life [7]. The gene discussed is CSF3; the disease is disorder of glycogen metabolism.